Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

BACKGROUND: In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine. OBJECTIVE: To identify individuals with initial viral suppression (plasma HIV-1 RNA set point <3.0 log(10) copies/ml...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Li, Jonathan Z., Brumme, Chanson J., Lederman, Michael M., Brumme, Zabrina L., Wang, Hongying, Spritzler, John, Carrington, Mary, Medvik, Kathleen, Walker, Bruce D., Schooley, Robert T., Kuritzkes, Daniel R.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3316607/
https://ncbi.nlm.nih.gov/pubmed/22479542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0034134
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars